US EditionPublished • loading... • Updated
Cabaletta Bio to Present Rese-Cel Data at ASGCT 2026 Meeting
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cabaletta Bio to Present Rese-Cel Data at ASGCT 2026 Meeting
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) will present clinical, translational and manufacturing data on its investigational CAR T therapy rese-cel at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston from May 11 to May 15, 2026. The presentations include early clinical and translational data from the lowest-dose cohort of rese-cel without preconditioning in pemphigus vulgaris patients enrolled in the RESET-PV…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
